Kazuhide Nakamura

Kazuhide Nakamura

Otsuka Pharmaceutical Co. Ltd. - Tokyo / Japan
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4971075
大塚製薬株式会社 大塚製薬株式会社
person_outline Kazuhide Nakamura's MOST POPULAR ARTICLES
1-) KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties K Nakamura, E Taguchi, T Miura, A Yamamoto, K Takahashi, F Bichat, ... Cancer research 66 (18), 9134-9142, 2006 2252006
2-) Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages M Murakami, S Iwai, S Hiratsuka, M Yamauchi, K Nakamura, Y Iwakura, ... Blood 108 (6), 1849-1856, 2006 2082006
3-) Novel Potent Orally Active Selective VEGFR-2 Tyrosine Kinase Inhibitors:  Synthesis, Structure−Activity Relationships, and Antitumor Activities of N-Phenyl-N‘-{4 … K Kubo, T Shimizu, S Ohyama, H Murooka, A Iwai, K Nakamura, ... Journal of medicinal chemistry 48 (5), 1359-1366, 2005 1652005
4-) A novel LSD1 inhibitor T-3775440 disrupts GFI1B-containing complex leading to transdifferentiation and impaired growth of AML cellsY Ishikawa, K Gamo, M Yabuki, S Takagi, K Toyoshima, K Nakayama, ...Molecular cancer therapeutics 16 (2), 273-284, 20171072017
5-) KRN633: a selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growthK Nakamura, A Yamamoto, M Kamishohara, K Takahashi, E Taguchi, ...Molecular cancer therapeutics 3 (12), 1639-1649, 2004912004